Home › Funds › AMI ASSET MANAGEMENT CORP › MDGL

AMI ASSET MANAGEMENT CORP position in MDGL

MADRIGAL PHARMACEUTICALS INC · Health Care

AMI ASSET MANAGEMENT CORP reported holding 2,135 shares of MDGL (MADRIGAL PHARMACEUTICALS INC) in its Q2 2026 13F filing — a position valued at US$1.1M, representing 0.07% of its reported portfolio and ranking #43 among its reported holdings. AMI ASSET MANAGEMENT CORP has disclosed MDGL holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

Latest position (Q2 2026)2.13K sh
Reported value held$1.15M
Portfolio Weight0.07%
First reportedQ4 2023
Last changeReduce
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How AMI ASSET MANAGEMENT CORP's MDGL position evolved

AMI ASSET MANAGEMENT CORP first disclosed a stake in MDGL in Q4 2023 at 4,773 shares (US$1.1M). The position peaked in Q1 2024 at 9,618 shares, worth US$2.6M. Across 11 filings, AMI ASSET MANAGEMENT CORP increased the stake 2 time(s), trimmed it 7 time(s) and left it unchanged 1 time(s). The most recent filing (Q2 2026) shows 2,135 shares valued at US$1.1M — a reduction of -478 shares quarter over quarter.. Notable position changes include a 102% increase in Q1 2024 (shares rose 5% over the following quarter), a 43% trim in Q2 2024 (shares fell 24% over the following quarter), a 37% trim in Q2 2025 (shares rose 52% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 4.77K $1.10M New
Q1 2024 9.62K $2.57M Add
Q2 2024 5.49K $1.54M Reduce
Q3 2024 5.01K $1.06M Reduce
Q4 2024 4.98K $1.54M Reduce
Q1 2025 5.50K $1.82M Add
Q2 2025 3.44K $1.04M Reduce
Q3 2025 3.43K $1.57M Hold
Q4 2025 2.75K $1.60M Reduce
Q1 2026 2.61K $1.37M Reduce
Q2 2026 2.13K $1.15M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About MDGL and 13F data

MDGL (MADRIGAL PHARMACEUTICALS INC) is a Health Care company. 48 other funds we track also report a position in MDGL — the largest reported positions include BAKER BROS. ADVISORS LP (US$1.15B), RTW INVESTMENTS, LP (US$1.07B), Janus Henderson Group (US$1.05B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding MDGL

All MDGL fund holders →

FAQ

How long has AMI ASSET MANAGEMENT CORP held MDGL?

AMI ASSET MANAGEMENT CORP has disclosed MDGL holdings in 11 of the last 11 reported quarters, going back to Q4 2023.

What is AMI ASSET MANAGEMENT CORP's current position in MDGL?

As of Q2 2026, AMI ASSET MANAGEMENT CORP holds 2.13K shares of MDGL (MADRIGAL PHARMACEUTICALS INC), valued at $1.15M, representing 0.07% of its reported portfolio and ranking #43.

Has AMI ASSET MANAGEMENT CORP been buying or selling MDGL?

In the latest 13F filing (Q2 2026), AMI ASSET MANAGEMENT CORP reduced its position in MDGL. The position peaked in Q1 2024 at 9.62K shares.

Which other funds hold MDGL?

Other major institutional holders of MDGL include BAKER BROS. ADVISORS LP, RTW INVESTMENTS, LP, Janus Henderson Group, among 48 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.